Lupin launches first branded generic alternative to Fostair in UK for treating asthma and COPD:

Lupin Ltd

Lupin Healthcare (UK) Limited, wholly-owned subsidiary of global pharma major Lupin Limited announced that following the

Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year, it has launched Luforbec® (beclometasone/formoterol) 100/6 dose pressurised metered dose inhaler (pMDI), making it available now to patients in the UK, with the potential to offer significant cost savings for the NHS, the company said in an exchange filing. The stock was trading at Rs 939.50, up Rs 14.75, or 1.60 percent.

News Source:- Moneycontrol

For Enquiry Fill The Form

    *Note:- Please provide a valid Email Id to receive OTP from bigprofitbuzz.com.

    Facebook Iconfacebook like buttonYouTube IconTwitter Icontwitter follow button